Edit

4BIO Capital

https://www.4biocapital.com

Last activity: 06.11.2025

Active

4BIO Capital is an international venture capital firm focused solely on the advanced therapies sector.

4BIO’s objective is to invest in, support, and grow early stage companies developing treatments in areas of high unmet medical need, with the ultimate goal of ensuring access to these potentially curative therapies for all patients. Specifically, it looks for viable, high-quality opportunities in cell and gene therapy, RNA-based therapy, targeted therapies, and the microbiome.

The 4BIO team comprises leading advanced therapy scientists and experienced life science investors who have collectively published over 250 scientific articles in prestigious academic journals including Nature, The Lancet, Cell, and the New England Journal of Medicine. 4BIO has both an unrivalled network within the advanced therapy sector and a unique understanding of the criteria that define a successful investment opportunity in this space.

For more information, please visit www.4biocapital.com

News

Portfolio

Mentions

Location: United Kingdom, England, Westminster

Employees: 11-50

Founded date: 2014

Investment Type: Venture Capital

Investment Stage: Pre-Seed; Seed; Series A

Twitter

Portfolio 8

Date	Name	Website	Total Raised	Location
06.10.2025	Trogenix	trogenix.com	$94.43M	United Kin...
10.07.2025	Actithera	actithera.com	$75.5M	Norway
13.11.2023	ViaNautis	vianautis.com	$25M	-
08.06.2022	LUCA Scien...	luca-science.com	$30.3M	Japan, Chu...
04.01.2022	Ray Therap...	raytherapeutics.com	$110M	United Sta...
20.04.2021	Code Bioth...	codebiotx.com	$85M	United Sta...
27.10.2020	SparingVis...	sparingvision.com	$202.94M	France, Il...
22.10.2020	Araris Bio...	ararisbiotech.com	$46.11M	Switzerlan...

News 59

Date	Title	Description
16.08.2024	4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity	-
16.08.2024	4BIO Capital Strengthens Advisory Board and Investment Team	-
16.08.2024	4BIO Capital Portfolio Company Hornet Therapeutics emerges from stealth with data published in Science demonstrating the first potential drug intervention for Epstein-Barr Virus (EBV) driven disease	-
10.01.2024	Development Bank of Japan invests in 4BIO Capital’s Ventures III fund	4BIO Ventures III targeting $200-300 million to unlock the treatments of the future by investing in advanced therapies and other emerging technologies
13.11.2023	4BIO Capital jointly leads $25 million Series A financing of ViaNautis Bio	- ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet clinical need
12.11.2023	Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical	AU ZH, SWITZERLAND, November 8, 2023 – Araris Biotech AG (“Araris”), a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), today announced they have entered a collaboration agreement under which Araris...
30.10.2023	SparingVision named a ‘Fierce 15’ Company by Fierce Biotech	SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, announces that it has been named by Fierce Biotech as one of 2023’s ‘Fierce 15’ biotechnology companies, designating it as one...
04.07.2023	Cell and gene therapy manufacturing: the next generation of startups	4BIO Capital portfolio company Ascend Gene and Cell Therapies has featured in a BioPharma Dive article from the State of Play series that takes a look at the emerging cell and gene therapy manufacturing companies
18.05.2023	4BIO Capital Participates in $130M Funding of New Gene and Cell Manufacturing Specialist Ascend	Expert transatlantic teams merge to establish Ascend as new facilitator for gene and cell therapy companies to translate product ideas into viable clinical programs
18.05.2023	4BIO Capital Portfolio Company Ray Therapeutics Closes Oversubscribed $100M Series A Financing	- Ray Therapeutics Closes Oversubscribed $100M Series A Financing
17.12.2022	4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A	Company’s proprietary end-to-end Encompass™ platform designs enhancement-targeting chimeric (ENTAC™) molecules
07.12.2022	Entact Bio Launch with $81M Series A to Develop Precision Medicines for Targeted Protein Enhancement	Launch fueled by syndicate of blue-chip investors co-led by Qiming Venture Partners USA and venBio Partners
02.12.2022	SparingVision’s lead asset SPVN06 clears IND application in the US for retinitis pigmentosa	SparingVision set to advance into the clinic with breakthrough gene-independent approach targeting retinitis pigmentosa (RP), one of the leading causes of blindness globally
22.11.2022	4BIO Capital Portfolio Company Redpin Therapeutics to be Acquired by Kriya Therapeutics	London & New York – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies and other emerging technologies, today announces the acquisition o...
04.10.2022	Araris Biotech Closes $24 Million Financing Round	AU ZH, SWITZERLAND / October 4, 2022 / Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing...
21.09.2022	4BIO Capital Portfolio Company Carisma Therapeutics and Sesen Bio Announce Merger Agreement	21 September 2022
17.09.2022	SparingVision Raises €75 Million Series B	LONDON– 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm unlocking the treatments of the future by investing in advanced therapies, including genomic medicines and other emerging technologies, OR a leading investo...
12.05.2022	Ray Therapeutics Receives $4M in Funding from the California Institute for Regenerative Medicine	27 April 2022
01.03.2022	Code Biotherapeutics Announces Collaboration with Takeda	Code Biotherapeutics, Inc. (Code Bio), a biotechnology company pioneering targeted non-viral delivery of genetic medicines, today announced a collaboration and option agreement with Takeda to leverage Code Bio’s proprietary targeted 3DNA® n...
13.12.2021	4BIO Capital to Use Insig AI’s Technology to Accelerate the Discovery of Innovative Investments	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has signed a software service agreement with Insig AI plc (AIM:INSG),...
02.12.2021	4BIO Capital Announces Strategic Partnership with Harbor Capital Advisors	London, 2 December 2021 – 4BIO Capital (“4BIO” or “the Group”), an international asset management firm focused solely on the advanced therapies sector, announces today that it has been appointed as a highly specialized asset manager for the...
13.10.2021	SparingVision announces strategic collaboration with Intellia Therapeutics	London, 13 October 2020 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announced today that its portfolio company SparingVision, a genomic medicine company deve...
20.04.2021	4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics...
20.04.2021	SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics	Paris, April 20, 2021 – SparingVision (the “Company”), a genomic medicines company developing vision saving treatments for ocular diseases, today announces it has entered into a definitive agreement to acquire GAMUT Therapeutics (“GAMUT”), ...
01.03.2021	4BIO Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announced it has become an investor in CARISMA Therapeutics, a biopharmaceutical company focu...
25.01.2021	4BIO Capital’s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces the publication of a systematic review paper entitled “The Clinical Landscape for A...
22.12.2020	Orchard Therapeutics Receives EC Approval for Treatment of Early-Onset Metachromatic Leukodystrophy	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, notes that portfolio company Orchard Therapeutics, a global leader in gene therapy, announced...
18.12.2020	Appointment of Professor Akiko Iwasaki to Scientific Advisory Board	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces the appointment of Professor Akiko Iwasaki to its Scientific Advisory Board (SAB)....
20.11.2020	ADC Therapeutics Announces FDA’s Acceptance of its Biologics License Application	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, notes that portfolio company ADC Therapeutics SA (“ADC” or the “Company”), a late clinical st...
22.10.2020	4BIO Capital invests in Araris Biotech AG’s CHF 15.2 million seed financing round	· Dmitry Kuzmin, Managing Partner, to join as Board member
21.10.2020	4BIO Capital leads SparingVision’s €44.5 million financing round	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces its investment in SparingVision, a genomic medicine company focused on ocular disea...
13.07.2020	4BIO Capital announces appointment of Professor Kenya Honda to Scientific Advisory Board	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces the appointment of Professor Kenya Honda to its Scientific Advisory Board (SAB)....
01.07.2020	4BIO Capital appoints Brian P. McVeigh as Venture Partner	LONDON & PHILADELPHIA – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces that it has appointed Brian P. McVeigh as Venture Partner based in the US....
08.06.2020	4BIO Capital announces strategic investment from Japanese pharmaceutical company Kyowa Kirin	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces that Kyowa Kirin Co., Ltd. (“Kyowa Kirin”, TSE:4151), a leading Japan-based global ...
20.05.2020	4BIO Capital portfolio company ADC Therapeutics SA closes an upsized IPO of over $267.6 million	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, notes that portfolio company ADC Therapeutics SA, a late clinical stage oncology-focused biot...
19.05.2020	4BIO Capital publishes review of AAV gene therapies in Cell & Gene Therapy Insights	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces the publication of a review paper entitled “Addressing the current limitations of A...
25.03.2020	4BIO Capital leads Redpin Therapeutics’ $15.5 million Series A	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces its investment in Redpin Therapeutics, Inc., a pioneering chemogenetics company dev...
01.11.2019	Data suggest gene, cell therapy trial initiations in Europe lag behind America — here's why	4BIO's Dmitry Kuzmin and Owen Smith enjoyed speaking to Natalie Grover at Endpoints on the state of cell & gene therapy trials in Europe and the US following yesterday’s report from the Alliance for Regenerative Medicine. We also discus...
30.09.2019	4BIO Capital appoints Philippe Fauchet, OBE, as Venture Partner, Japan	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces today that it has appointed Philippe Fauchet, OBE, as a Venture Partner based in Ja...
09.09.2019	4BIO Capital raises $50 million in first close of new advanced therapies fund	4BIO Ventures II fund solely focused on advanced therapies targeting $150 million final close
25.02.2019	Spark Therapeutics enters into definitive merger agreement with Roche	Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion. Spark Therapeutics will continue its operations in Philadelphia as an independent company within the Roche Group Transaction expect...
22.02.2019	4BIO portfolio company Orchard Therapeutics announces ADA-SCID follow-on results	Orchard Therapeutics plc (Nasdaq:ORTX) presents Two-Year Follow-Up Data versus historical control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID. 100% overall survival and 100% event free survival in patients treated wit...
10.11.2018	EGLSF I wins two EuroHedge Emerging Fund Management Awards	4BIO Capital is proud to announce that EG Life Sciences Fund I Ltd (EGLSF 1, or the “Fund”), has won two industry awards at the 2018 EuroHedge Emerging Fund Management Awards Ceremony, in recognition of the fund’s strong performance since l...
01.11.2018	4BIO portfolio company Orchard Therapeutics goes public	Orchard Therapeutics plc (Nasdaq:ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies, today announced the pricing of it...
13.08.2018	4BIO portfolio company Orchard Therapeutics Announces $150 Million Series C Financing	Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financi...
10.05.2018	Fellowship of the Royal Society elections	4BIO Capital extends warm congratulations to Professor Dimitri Kullman, member of our Scientific Advisory Board, on his election as Fellow of the Royal Society in recognition of his outstanding contribution to science. Professor Kullman is ...
13.04.2018	GSK Hands Off Rare Disease Gene Therapy Portfolio to Orchard Therapeutics	GlaxoSmithKline (GSK) said today it will hand off its rare disease gene therapy portfolio — including its European-approved gene therapy Strimvelis™ — to two-year-old startup Orchard Therapeutics in return for taking a 19.9% stake in the ac...
24.03.2018	TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval	TiGenix NV (Euronext Brussels and NASDAQ: TIG) (“TiGenix”) and Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that the European Commission (EC) has approved Alofisel (darvadstrocel), previously Cx601, for the t...
05.01.2018	Takeda announces its intention to acquire TiGenix	TiGenix NV ("TiGenix") (Euronext Brussels and NASDAQ: "TIG"), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel ther...
03.01.2018	Spark Therapeutics Announces Pricing and First-of-their-kind Patient Access Programs
20.12.2017	4BIO Capital participates in $110M Series B Financing of Orchard Therapeutics	Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the completion of an oversubscribed $110 million (£85 million) Series B fin...
19.12.2017	FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl)	Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that the U.S. Food and Drug Administration (FDA) has approved LUXTURNA™ (voretigene nep...
-	4BIO Capital Portfolio Company Carisma to Collaborate with Moderna	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that its portfolio company Carisma Therapeutics Inc., a biopharmaceutical pio...
-	4BIO Capital co-leads $30 million (¥3.86 Billion) oversubscribed Series B financing in LUCA Science	- Financing reflects the potential of mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs
-	4BIO Capital announces promotion of Owen Smith to Partner and Vasily Fedorin to COO	LONDON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announced the promotion of Owen Smith, MSc (Oxon), CPFA, to Partner and Vasily Fedorin, PhD, to Chie...
-	4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has led a $6 million seed financing round in Ray Therapeutics (or “th...
-	Development Bank of Japan invests in 4BIO Capital’s Ventures III fund	-
-	Development Bank of Japan invests in 4BIO Capital’s Ventures III fund	4BIO Ventures III targeting $200-300 million to unlock the treatments of the future by investing in advanced therapies and other emerging technologies
-	4BIO Capital Portfolio Company Code Biotherapeutics Closes an Oversubscribed $75 Million Series A	7 June 2022

Mentions in press and media 49

Date	Title	Description
06.11.2025	DIGIT Deal Roundup \| October 2025	Welcome to October 2025’s DIGIT Deal Roundup. Christmas came very early for a raft of Scottish firms last month, with tens of millions in fresh investment targeting Scotland’s medtech stars, robot builders, EV makers, and agri-tech innovato...
13.10.2025	Trogenix: $95 Million Series A Closed For Advancing Clinical Development Of Curative Cancer Therapies	Trogenix, a biotech company dedicated to developing innovative therapies for cancer treatment, announced the closing of its Series A financing round at £70 million (approximately $95 million). This funding will accelerate the development of...
07.10.2025	Precision Oncology Pioneer Trogenix Secures Landmark €80M Series A for Curative Cancer Fight	Trogenix, an Edinburgh-based biotech, secured a monumental €80 million Series A funding. This capital empowers its pursuit of curative cancer treatments for aggressive solid tumors. The firm's Odysseus platform uses advanced gene control an...
06.10.2025	Edin Uni Spinout Trogenix Raises £70M to Treat Aggressive Cancers	University of Edinburgh spinout Trogenix, which is developing curative therapies for aggressive, treatment-resistant cancers, has completed Series A financing of £70 million. The funding will allow the biotech company to rapidly advance its...
06.10.2025	Edinburgh-based BioTech Trogenix lands €80 million to accelerate curative cancer treatments	Trogenix Ltd, a Scottish BioTech company dedicated to innovative cancer therapies, announced the completion of its Series A financing, raising €80 million, to advance its pipeline of potentially curative cancer therapies across multiple agg...
30.07.2025	NUS Enterprise pledges $116 M to accelerate growth of deep tech start-ups in Singapore	To support the expansion of deep tech start-ups, NUS Enterprise, the entrepreneurial division of the National University of Singapore (NUS), Singapore’s premier comprehensive research university, is investing S$150 million ($116 million) to...
22.07.2025	First-of-its-kind Venture Capital Programme in Asia launches as NUS commits S$150 million to boost growth of deep tech start-ups	NUS will invest S$50 million (US$39 million) in selected venture capital (VC) firms to provide structured support for NUS tech start-ups. S$100 million will be committed to an autonomous investment fund focused on NUS-affiliated start-ups, ...
22.07.2025	Singapore's NUS launches $116m VC programme to back deep tech startups	NUS Enterprise, the entrepreneurial arm of the National University of Singapore (NUS), has committed S$150 million ($116 million) for the NUS VC Programme that aims to support early-stage tech innovation. NUS will commit S$50 million ($39 m...
14.07.2025	Actithera Secures $75.5 Million to Propel Precision Radioligand Therapies	Actithera, a cutting-edge biotech firm, recently secured $75.5 million in oversubscribed Series A funding. This significant capital injection powers their precision radioligand therapy (RLT) initiatives. Funds will advance their lead FAP as...
10.07.2025	Actithera: $75.5 Million Series A Raised For Transforming Precision Radioligand Therapy	Actithera, a biotech company specializing in radiopharmaceuticals, has secured $75.5 million in an oversubscribed Series A financing round. This funding will help advance their lead FAP (Fibroblast Activation Protein) asset into clinical de...
09.07.2025	Actithera Raises $75.5M in Series A Funding	Actithera, an Oslo, Norway-, and Cambridge, MA-based radiopharmaceutical biotech company developing radioligand therapies (RLTs), raised $75.5M in Series A funding. The round was led by M Ventures and new investors Hadean Ventures, Sofinnov...
17.03.2025	Taiho Pharmaceutical to acquire Araris Biotech for up to USD 1.1 billion	Araris is a spin-off company of the Paul-Scherrer-Institute in Switzerland and pioneering the development of best-in-class ADCs with superior design, high linker solubility and simple manufacturing that address the shortcomings of current ...
17.03.2025	4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion	Press Release 4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion Araris will receive USD 400 million upfront, with the potential for additional near-term and long-term milestone p...
17.03.2025	4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion	Press Release 4BIO Capital Portfolio Company Araris Biotech to be Acquired by Taiho Pharmaceutical for up to USD 1.14 billion Araris will receive USD 400 million upfront, with the potential for additional near-term and long-term milestone p...
05.03.2025	Ascend Advanced Therapies Appoints John Chiminski as Chair and Karen Flynn as Independent Director	ROCKVILLE, Md., March 5, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), a gene to GMP advanced therapy development partner, today announced the appointment of John Chiminski and Karen Flynn as non-executive members of its Board of...
18.11.2024	Trogenix unveils odyssey to find one-time tumor drugs with 'unprecedented selectivity'	A spinout from the University of Edinburgh in Scotland is already equipped with 15 million pounds sterling ($19 million) in seed funding as the newly unveiled biotech continues its mission to find one-time cancer treatments. Trogenix, which...
05.11.2024	Houston's Innovation Landscape: Navigating Challenges and Embracing Opportunities	Houston is a city of dreams and determination. It’s a melting pot of innovation, where entrepreneurs are forging paths in uncharted territories. The recent Houston Innovation Awards highlighted this spirit, showcasing the wisdom of finalist...
04.11.2024	Overheard: 2024 Houston Innovation Awards finalists share top advice for fellow founders	There's a great deal of advice swirling around the world today about how to find success business. Why not take it from mentors and founders with a proven track record, like the finalists for this year's Houston Innovation Awards? From how ...
04.11.2024	4BIO Capital Strengthens Investment Team	Press Release LONDON, 4 November 2024 – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced and emerging therapies sector, announces today the appointments of Dr. Therese (Thera) Liecht...
24.10.2024	Houston's Innovation Surge: Biotech Breakthroughs and Mars Simulations	Houston is a city where innovation thrives. It’s a melting pot of ideas, where science meets ambition. Recently, two stories have emerged that highlight this vibrant ecosystem: a groundbreaking biotech company and a NASA Mars simulation mis...
23.10.2024	NASA taps 4 participants for Mars habitat simulation mission in Houston	Four individuals have been selected to go to Mars. Well, sort of. Obaid Alsuwaidi, Kristen Magas, Tiffany Snyder, and Anderson Wilder were picked by NASA to live for 45 days in a 650-square-foot Mars simulation located at Johnson Space Cent...
23.10.2024	Clinical-stage Houston cell therapy company closes $28.4M oversubscribed series A	An emerging biotech company in Houston has closed its series A with outsized success. March Biosciences' oversubscribed raise brought in $28.4 million of financing with Mission BioCapital and 4BIO Capital leading the pack of investors. The ...
13.11.2023	4BIO Capital jointly leads $25 million Series A financing of ViaNautis Bio	- ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet clinical need
18.05.2023	4BIO Capital Portfolio Company Ray Therapeutics Closes Oversubscribed $100M Series A Financing	- Ray Therapeutics Closes Oversubscribed $100M Series A Financing
18.05.2023	4BIO Capital Participates in $130M Funding of New Gene and Cell Manufacturing Specialist Ascend	Expert transatlantic teams merge to establish Ascend as new facilitator for gene and cell therapy companies to translate product ideas into viable clinical programs
16.05.2023	4BIO Capital Portfolio Company Ray Therapeutics Closes Oversubscribed $100M Series A Financing to Advance Optogenetic Gene Therapies for Blinding Diseases	-
04.10.2022	Araris Biotech Closes $24 Million Financing Round
15.09.2022	50+ венчурных фондов с российскими корнями, которые инвестируют в стартапы в 2022 году	В начале сентября 2022 г. аналитики Softline Venture Partners выпустили карту фондов с российскими “корнями”, инвестирующих в стартапы в 2022 году. Это как частные, так и государственные венчурные фонды и инвестиционные фирмы, которые либо ...
07.06.2022	4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed $75 Million Series A Financing	Press Release 4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed $75 Million Series A Financing 7 June 2022 London & Greater Philadelphia – 4BIO Capital (“4BIO” or “the Group”), an international ventur...
06.06.2022	4BIO Capital co-leads $30.3 million (¥3.86 Billion) oversubscribed Series B financing in LUCA Science	Press Release 4BIO Capital co-leads $30.3 million (¥3.86 Billion) oversubscribed Series B financing in LUCA Science Financing reflects the potential of mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tiss...
02.12.2021	4BIO Capital Announces Strategic Partnership with Harbor Capital Advisors	4BIO Capital Announces Strategic Partnership with Harbor Capital Advisors 4BIO Capital appointed as highly specialized asset manager for Harbor’s disruptive innovation strategy after competitive manager due diligence process Partnership is ...
02.12.2021	4BIO Capital Announces Strategic Partnership with Harbor Capital Advisors	4BIO Capital Announces Strategic Partnership with Harbor Capital Advisors 4BIO Capital appointed as highly specialized asset manager for Harbor’s disruptive innovation strategy after competitive manager due diligence process Partnership is ...
20.04.2021	4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics...
01.03.2021	10 start-ups and a new fellowship program at the University of Basel	Over the last years the University of Basel was strongly pivoting towards supporting homegrown start-ups & entrepreneurial action and this increasing support led to tangible results. In 2019 the number of start-ups increased to 9, in 20...
01.03.2021	10 start-ups and a new fellowship program at the University of Basel
22.10.2020	A CHF 15.2 Million seed investment brings Araris Biotech a step further
22.10.2020	4BIO Capital invests in Araris Biotech AG’s CHF 15.2 million seed financing round	· Dmitry Kuzmin, Managing Partner, to join as Board member
22.10.2020	A CHF 15.2 Million seed investment brings Araris Biotech a step further	There are nine antibody-drug conjugates (ADC) approved by the FDA; however, many of them cannot be dosed high enough to elicit efficacy. This is due to systemic toxicity often caused by linker instability or heterogeneous distributions of t...
21.10.2020	4BIO Capital leads SparingVision’s €44.5 million financing round	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces its investment in SparingVision, a genomic medicine company focused on ocular disea...
20.05.2020	4BIO Capital portfolio company ADC Therapeutics SA closes an upsized IPO of over $267.6 million	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, notes that portfolio company ADC Therapeutics SA, a late clinical stage oncology-focused biot...
25.03.2020	4BIO Capital leads Redpin Therapeutics’ $15.5 million Series A	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces its investment in Redpin Therapeutics, Inc., a pioneering chemogenetics company dev...
09.09.2019	Top tech startup news for today, Monday, September 9, 2019	Good morning! Below are some of the top tech startup news for today, Monday, September 9, 2019. Amazon set its eye on India with major million dollar investment. Facing steep competition from Walmart in India, Amazon just opened a new 9.5-...
09.09.2019	4BIO Capital raises $50 million in first close of new advanced therapies fund	4BIO Ventures II fund solely focused on advanced therapies targeting $150 million final close
09.09.2019	4BIO Capital secures$50 million for its Ventures II fund to invest 8 to 12 startups developing advanced therapies	4BIO Capital, a London-based biotech venture capital firm, has raised the first $50 million for a new $150 million 4BIO Ventures II fund to invest in “advanced therapies” such as gene and cell therapy. The firm is expected to raised the tot...
09.09.2019	4BIO Capital Raises $50M for Second Venture Fund	4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, announces today that it has completed the first close of its second venture fund, 4BIO Ventures II. Over $50 million of capital has been co...
13.08.2018	4BIO portfolio company Orchard Therapeutics Announces $150 Million Series C Financing	Orchard Therapeutics, a leading commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the completion of an oversubscribed $150 million Series C financi...
20.12.2017	4BIO Capital participates in $110M Series B Financing of Orchard Therapeutics	Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, today announced the completion of an oversubscribed $110 million (£85 million) Series B fin...
-	4BIO Capital co-leads $30 million (¥3.86 Billion) oversubscribed Series B financing in LUCA Science	- Financing reflects the potential of mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs
-	4BIO Capital Leads $6 Million Seed Financing in Ray Therapeutics	LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has led a $6 million seed financing round in Ray Therapeutics (or “th...

4BIO Capital

Portfolio 8

News 59

Mentions in press and media 49

Reviews 0